

# Ute Eisenberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9030409/publications.pdf>

Version: 2024-02-01

68

papers

3,029

citations

218662

26

h-index

161844

54

g-index

73

all docs

73

docs citations

73

times ranked

4094

citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. <i>Transplantation</i> , 2022, 106, 1215-1226.	1.0	7
2	Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection. <i>Frontiers in Medicine</i> , 2022, 9, 816555.	2.6	4
3	Influence of Immunosuppressive Regimen on Diffusivity and Oxygenation of Kidney Transplants—Analysis of Functional MRI Data from the Randomized ZEUS Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3284.	2.4	2
4	Norovirus Infections in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2655-2660.	1.0	4
5	Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). <i>Viruses</i> , 2021, 13, 756.	3.3	130
6	Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies. <i>Clinical Immunology</i> , 2021, 226, 108698.	3.2	5
7	Development Of De Novo Donor-Specific HLA Antibodies and ABMR in Renal Transplant Patients Depends on CYP3A5 Genotype. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	3
8	Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation. <i>Diagnostics</i> , 2021, 11, 1688.	2.6	1
9	Establishment of an ELISpot Assay to Detect Cellular Immunity against <i>S. pneumoniae</i> in Vaccinated Kidney Transplant Recipients. <i>Vaccines</i> , 2021, 9, 1438.	4.4	7
10	P1782INFLUENCE OF IMMUNOSUPPRESSIVE REGIMEN ON OXYGENATION AND DIFFUSIVITY OF KIDNEY TRANSPLANTS - ANALYSIS OF FUNCTIONAL MRI DATA FROM THE RANDOMIZED ZEUS STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
11	Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. <i>Bioscience Reports</i> , 2020, 40, .	2.4	4
12	Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients. <i>Vaccines</i> , 2019, 7, 84.	4.4	9
13	Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV- viremic donors into HCV- negative recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13146.	1.7	26
14	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	2.9	12
15	Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants. <i>BMC Nephrology</i> , 2019, 20, 167.	1.8	3
16	Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13088.	1.7	8
17	Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. <i>BMC Nephrology</i> , 2019, 20, 430.	1.8	11
18	Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. <i>Transplantation Direct</i> , 2019, 5, e419.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. <i>Transplant Immunology</i> , 2018, 47, 10-17.	1.2	10
20	Effect of ABO incompatibility on Tâ€cell flow cytometry crossâ€match results prior to living donor kidney transplantation. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 623-630.	1.5	4
21	Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 54-64.	0.7	12
22	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. <i>BMC Nephrology</i> , 2018, 19, 237.	1.8	14
23	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , 2018, 19, 154.	1.8	3
24	Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. <i>PLoS ONE</i> , 2018, 13, e0188695.	2.5	12
25	Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients. <i>Transplantation</i> , 2017, 101, 980-986.	1.0	42
26	Rescue allocation and recipient oriented extended allocation in kidney transplantation-influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs. <i>Transplant International</i> , 2017, 30, 1226-1233.	1.6	10
27	Transplanting HCV-Infected Kidneys into Uninfected Recipients. <i>New England Journal of Medicine</i> , 2017, 377, 1103-1105.	27.0	29
28	Glomerulocapillary miRNA response to HLA-class I antibody in vitro and in vivo. <i>Scientific Reports</i> , 2017, 7, 14554.	3.3	8
29	Calcification Propensity and Survival among Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 239-248.	6.1	115
30	Renal Blood Oxygenation Levelâ€dependent Imaging in Longitudinal Follow-up of Donated and Remaining Kidneys. <i>Radiology</i> , 2016, 279, 795-804.	7.3	20
31	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. <i>Clinical Nephrology</i> , 2016, 85 (2016), 215-225.	0.7	9
32	The Reuse of Immunoabsorption Columns in ABO-Incompatible Kidney Transplantation Is Efficient. <i>Transplantation</i> , 2015, 99, 1030-1035.	1.0	30
33	Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study. <i>American Journal of Transplantation</i> , 2015, 15, 119-128.	4.7	109
34	Living Renal Allograft Transplantation: Diffusion-weighted MR Imaging in Longitudinal Follow-up of the Donated and the Remaining Kidney. <i>Radiology</i> , 2014, 270, 800-808.	7.3	39
35	Reference Values and Factors Associated With Renal Resistive Index in a Family-Based Population Study. <i>Hypertension</i> , 2014, 63, 136-142.	2.7	97
36	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. <i>Transplant International</i> , 2014, 27, 1192-1204.	1.6	6

#	ARTICLE	IF	CITATIONS
37	The Swiss Systemic lupus erythematosus Cohort Study (SSCS) â€” cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly, 2014, 144, w13990.	1.6	31
38	Heritability, determinants and reference values of renal length: a family-based population study. European Radiology, 2013, 23, 2899-2905.	4.5	47
39	Medication Adherence Assessment. Transplantation, 2013, 96, 245-250.	1.0	73
40	Arterial Stiffness Depends on Serum Ionized Calcium Levels During Dialysis With Regional Citrate Anticoagulation. Artificial Organs, 2013, 37, 467-474.	1.9	10
41	Serum cytokine profile in patients with active lupus nephritis. Cytokine, 2012, 60, 410-416.	3.2	76
42	Threeâ€”year followâ€”up of human transplanted kidneys by diffusionâ€”weighted MRI and blood oxygenation levelâ€”dependent imaging. Journal of Magnetic Resonance Imaging, 2012, 35, 1133-1138.	3.4	43
43	Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study. American Journal of Transplantation, 2012, 12, 1528-1540.	4.7	77
44	Impact of renal insufficiency on clinical outcomes in patients with critical limb ischemia undergoing endovascular revascularization. Journal of Vascular Surgery, 2011, 53, 1589-1597.	1.1	30
45	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, The, 2011, 377, 837-847.	13.7	326
46	Donor Effect on Cortical Perfusion Intensity in Renal Allograft Recipients: A Paired Kidney Analysis. American Journal of Nephrology, 2011, 33, 530-536.	3.1	5
47	Evaluation of renal allograft function early after transplantation with diffusion-weighted MR imaging. European Radiology, 2010, 20, 1374-1383.	4.5	114
48	Meta-Analyses Qualify Metzincins and Related Genes as Acute Rejection Markers in Renal Transplant Patients. American Journal of Transplantation, 2010, 10, 286-297.	4.7	24
49	Comparison of physiological triggering schemes for diffusionâ€”weighted magnetic resonance imaging in kidneys. Journal of Magnetic Resonance Imaging, 2010, 31, 1144-1150.	3.4	26
50	Renal Resistance Index in Renal Allograft Recipients: A Role for ADMA. American Journal of Kidney Diseases, 2009, 54, 327-333.	1.9	6
51	Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor. Clinical Transplantation, 2009, 23, 499-504.	1.6	8
52	FoxP3 Positive T Cells in Graft Biopsies From Living Donor Kidney Transplants After Donor-Specific Transfusions. Transplantation, 2009, 87, 138-142.	1.0	3
53	Pulse contour analysis: a valid assessment of central arterial stiffness in children?. Pediatric Nephrology, 2008, 23, 439-444.	1.7	15
54	PTH and 1.25 vitamin D response to a low-calcium diet is associated with bone mineral density in renal stone formers. Nephrology Dialysis Transplantation, 2008, 23, 2563-2570.	0.7	19

#	ARTICLE	IF	CITATIONS
55	Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrology Dialysis Transplantation, 2007, 22, 2362-2365.	0.7	53
56	FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia. American Journal of Transplantation, 2006, 6, 2912-2921.	4.7	145
57	Arterial Stiffness Assessed by Digital Volume Pulse Correlates With Comorbidity in Patients With ESRD. American Journal of Kidney Diseases, 2006, 48, 456-463.	1.9	47
58	Functional Evaluation of Transplanted Kidneys with Diffusion-weighted and BOLD MR Imaging: Initial Experience. Radiology, 2006, 241, 812-821.	7.3	239
59	ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrology Dialysis Transplantation, 2005, 20, 1392-1399.	0.7	150
60	The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrology Dialysis Transplantation, 2005, 20, 1311-1314.	0.7	160
61	The Renal Arterial Resistance Index and Renal Allograft Survival. New England Journal of Medicine, 2003, 349, 115-124.	27.0	363
62	Protocol biopsy program after renal transplantation: structure and first results. Transplantation Proceedings, 2002, 34, 2238-2239.	0.6	25
63	The tellâ€œtale urinary chloride. Nephrology Dialysis Transplantation, 2001, 16, 1066-1068.	0.7	7
64	Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients. Transplantation Proceedings, 1999, 31, 1312-1313.	0.6	13
65	Tacrolimus for Steroid- and OKT3-Resistant Rejection in Kidney Recipients. Transplantation Proceedings, 1998, 30, 1251-1253.	0.6	4
66	Gemella morbillorum-spondylodiscitis in a patient with a renal graft. Nephrology Dialysis Transplantation, 1998, 13, 1565-1567.	0.7	17
67	The Assessment of Biomarkers to Detect Nephrotoxicity Using an Integrated Database. Environmental Research, 1997, 75, 23-33.	7.5	55
68	Cathepsin B and L in Isolated Proximal Tubular Segments during Acute and Chronic Proteinuria. Kidney and Blood Pressure Research, 1995, 18, 89-96.	2.0	5